Stock listing

NYSE American:NSRX Nasus Pharma Ltd. Stock

Home listing (NYSE American) of Nasus Pharma Ltd.

Follow Nasus Pharma Ltd. into a list and get an email when it puts out news.

Share price · AMEX:NSRX

$2.29 USD -0.41 (-15.2%)

Close on Nov 20, 2026

Past year -67.3% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$2.20 – $2.59 USDNov 20, 2026
Volume
33,961 sharesNov 20, 2026
Market cap
$26.82M USDAt the close on Nov 20, 2026 · price × 11.71M shares outstanding
52-week range
$1.98 – $9.50 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$58,852 USDMedian day 13,416 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Nasus Pharma Ltd. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NYSE American:NSRX · Home$2.29 USD-0.41 (-15.2%)33,961$2.50$2.59$2.20$2.70Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · AMEX:NSRX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$2.29-0.41-15.2%$2.50$2.59$2.2033,961
$2.70+0.09+3.4%$2.70$2.74$2.6811,659
$2.61-0.05-1.9%$2.59$2.61$2.5414,959
$2.66-0.21-7.3%$2.75$2.855$2.5125,494
$2.87+0.05+1.8%$2.935$2.935$2.814,675
$2.82-0.09-3.1%$2.90$2.914$2.768,554
$2.91-0.075-2.5%$2.90$3.025$2.894,779
$2.985+0.05+1.7%$2.939$2.985$2.8613,764
$2.935+0.115+4.1%$2.763$2.96$2.76317,555
$2.82-0.09-3.1%$2.82$3.01$2.786,990
$2.91-0.01-0.3%$2.865$3.015$2.7534,665
$2.92-0.28-8.8%$3.25$3.36$2.9126,352
$3.20+0.0010.0%$3.31$3.395$3.1015,734
$3.199+0.129+4.2%$3.10$3.32$3.104,749
$3.07-0.12-3.8%$3.23$3.27$3.074,888
$3.19-0.15-4.5%$3.34$3.40$3.1910,574
$3.34+0.02+0.6%$3.39$3.40$3.195,384
$3.32-0.17-4.9%$3.285$3.50$3.28510,981
$3.490.000.0%$3.41$3.607$3.4115,034
$3.49+0.26+8.0%$3.20$3.585$3.0935,236
$3.23+0.17+5.6%$3.31$3.61$3.1233,361
$3.06-0.18-5.6%$3.20$3.63$3.0344,422
$3.24+0.035+1.1%$3.21$3.33$3.2119,851
$3.205+0.025+0.8%$3.13$3.39$3.0919,076
$3.18+0.015+0.5%$3.09$3.24$3.0915,042
$3.165-0.015-0.5%$3.22$3.22$3.056,515
$3.18+0.02+0.6%$3.23$3.31$3.0813,342
$3.16-0.16-4.8%$3.22$3.33$3.1013,416
$3.32-0.19-5.4%$3.33$3.44$3.24230,876
$3.51-0.12-3.3%$3.63$3.661$3.4416,920
$3.63-0.145-3.8%$3.78$3.78$3.5014,033
$3.775-0.065-1.7%$3.855$3.91$3.7579,572
$3.84-0.01-0.3%$3.88$3.913$3.7717,224
$3.85-0.07-1.8%$4.00$4.03$3.809,569
$3.92+0.105+2.8%$3.82$4.10$3.7928,711
$3.815+0.125+3.4%$4.00$4.007$3.7628,616
$3.69+0.12+3.4%$4.00$4.00$3.6057,383
$3.57-0.02-0.6%$3.76$3.79$3.53837,356
$3.59+0.11+3.2%$3.69$3.78$3.35115,666
$3.480.000.0%$3.50$3.595$3.42520,955
$3.48-0.16-4.4%$3.35$3.50$3.353,940
$3.64+0.07+2.0%$3.57$3.79$3.5014,915
$3.57+0.13+3.8%$3.48$3.68$3.4512,454
$3.44-0.09-2.5%$3.46$3.53$3.356,426
$3.530.000.0%$3.35$3.58$3.3512,021
$3.53+0.07+2.0%$3.535$3.586$3.467,639
$3.46-0.13-3.6%$3.64$3.72$3.4110,949
$3.59-0.06-1.6%$3.62$3.767$3.4518,441
$3.65+0.245+7.2%$3.262$3.80$3.26221,174
$3.405+0.055+1.6%$3.498$3.50$3.4054,210
$3.35-0.20-5.6%$3.16$3.477$3.1610,715
$3.55-0.33-8.5%$3.47$3.565$3.174,443
$3.88+0.145+3.9%$3.53$3.973$3.478,676
$3.735-0.015-0.4%$3.53$3.735$3.53829
$3.75-0.02-0.5%$3.515$3.765$3.2315,098
$3.77-0.055-1.4%$4.037$4.037$3.681,894
$3.825-0.259-6.3%$3.85$4.08$3.4315,677
$4.084-0.016-0.4%$3.902$4.10$3.874,658
$4.100.000.0%$3.985$4.10$3.98414,574
$4.10+0.05+1.2%$4.05$4.10$4.058,827
$4.05-0.05-1.2%$4.09$4.09$3.8694,463
$4.10+0.03+0.7%$4.08$4.10$3.9910,210
$4.07+0.07+1.8%$3.98$4.07$3.76517,392
$4.00+0.15+3.9%$3.805$4.00$3.65529,900
$3.85+0.01+0.3%$3.665$3.85$3.5111,200
Ticker
NYSE American:NSRX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NYSE American
Currency
USD

What changed lately

Latest news

All Nasus Pharma Ltd. news

Nasus Pharma Ltd. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
16 in the last 12 months · 24 in all · newest Nov 16, 2026 · oldest 2025
Decks
11 decks · latest July 2026

Where Nasus Pharma Ltd. is listed

ListingExchangeCountryCurrency
NYSE American:NSRX · Home listing · This pageNYSE AmericanUnited StatesUSD
BOATS:NSRXBOATSUnited StatesUSD

Valuation

Price/book 2.4× against a median of 1.9×: 7th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$15.11M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
2.4×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
0.99

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Nasus Pharma Ltd. · AMEX:NSRXUS$26.82MUS$15.11Mn/an/an/a2.4×n/a0.0×0.99
Holy Stone Healthcare Co., Ltd. · TPEX:4194US$27.49MUS$25.08Mn/an/an/a7.3×n/a0.0×n/a
SoftOx Solutions AS · OSL:SOFTXUS$27.28MUS$25.25Mn/an/an/a11.6×n/a0.0×n/a
Edesa Biotech, Inc. · NASDAQ:EDSAUS$27.02MUS$16.72Mn/an/an/a3.1×n/a0.0×0.47
Amplia Therapeutics Ltd. · ASX:ATXUS$26.84MUS$8.63Mn/an/an/a1.0×n/a0.0×n/a
Telomir Pharmaceuticals, Inc. · NASDAQ:TELOUS$26.82MUS$22.30Mn/an/an/a6.1×n/a0.0×1.74
Aprogen, Inc · KRX:007460US$26.80MUS$21.45Mn/a0.2×n/a0.6×−60.1%0.6×n/a
BriaCell Therapeutics Corp · TSX:BCTUS$26.79MUS$6.25Mn/an/an/a1.7×n/a0.0×1.07
Alterity Therapeutics Ltd. · ASX:ATHUS$26.76MUS$2.18Mn/an/an/a0.9×n/a0.0×n/a
EyePoint, Inc. · NASDAQ:EYPTUS$26.65M−US$72.44Mn/a−28.1×n/a0.3×n/a0.2×1.36
PolTREG Spolka Akcyjna · GPW:PTGUS$26.08MUS$22.35Mn/a378×n/a2.2×n/a0.1×n/a
Median of the othersUS$26.81MUS$19.08M0.2×1.9×−60.1%0.0×1.22

Forecasts

Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
16.50 USD · Analysts' mean
EPS, year to Dec 2026
-1.13 · 4 analysts

Team and board

Officers

OfficerRole
Brendan O’GradyChief Executive Officer, Board Member
Eyal RubinExecutive Vice President and Chief Financial Officer
Nir SassiChief Financial Officer
Dalia MegiddoCo-founder, Board Member, Chief Development Officer
Udi GilboaExecutive Chairman

Board

DirectorRole
Udi GilboaExecutive Chairman
Brendan O’GradyChief Executive Officer, Board Member
Dalia MegiddoCo-founder, Board Member, Chief Development Officer
David SilbermanBoard Member
Isaac IsraelBoard Member
Ronnie HershmanBoard Member
Sharon ShachamBoard Member

Events

QuarterResultsShare move
Q4 2025Feb 25, 2026−3.0%
Q3 2025Dec 3, 2025−6.5%
Q2 2025Sep 3, 2025−0.4%
Q4 2024Mar 21, 2025

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (July 2026)Investor deck44 slidesJuly 2026
Investor Presentation (June 2026)Investor deck44 slidesJun 9, 2026
Investor Presentation (March 2026)Investor deck44 slidesMarch 2026
Investor Presentation (February 2026)Investor deck67 slidesFeb 26, 2026
Investor Presentation (January 2026)Investor deck48 slidesJanuary 2026
Investor Presentation (December 2025)Investor deck31 slidesDecember 2025
Investor Presentation (November 2025)Investor deck31 slidesNovember 2025
Investor Presentation (November 2025)Investor deck30 slidesNovember 2025
Investor Presentation (October 2025)Investor deck30 slidesOctober 2025
Investor Presentation (August 2025)Investor deck26 slidesAugust 2025
All 11 decks
DeckKindSlidesDate
IPO Roadshow (July 2025)IPO roadshow29 slidesJul 30, 2025

Open Decks

Financings

RaiseDate
Private placement of ordinary shares and accompanying warrants
Closed: US$15M raised · US$5.565 a share · 1 warrant at US$6.53 for 24 months · Citizens Capital Markets +1
Dealers: Citizens Capital Markets (lead), Laidlaw & Company (UK) Ltd.
Insiders: Certain members of the Company's Board of Directors are participating
Use of proceeds: Advance pivotal clinical development of NS002 for anaphylaxis, start first-in-human studies for other pipeline products, working capital and general purposes
Feb 13, 2026
Public offering of ordinary shares
Closed: US$10M raised · US$8 a share · Laidlaw & Company (UK) Ltd. +1
Dealers: Laidlaw & Company (UK) Ltd. (co-lead), Craft Capital Management LLC (co-lead)
Use of proceeds: Development of intranasal Epinephrine program, including manufacturing scale-up and additional Phase 2 studies; general corporate purposes and working capital
Aug 14, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$8.00 a share on Aug 12, 2025.

Price
US$8.00 a share
Shares offered
1,250,000 ordinary shares
Offering size
US$10 million
Listing
NSRX on NYSE American
Underwriters
Laidlaw & Company (UK) Ltd., CRAFT CAPITAL MANAGEMENT LLC · In the order on the cover
Shares delivered
On or about Aug 14, 2025

Steps

StepWhen
Draft sent to the SEC in confidenceAug 30, 2024
Filed publiclyJul 9, 2025
Amended twiceNewest Aug 7, 2025
Shares registered with an exchangeAug 8, 2025
Declared effective by the SECAug 12, 2025
Final prospectus, with the priceAug 14, 2025

Filings

FilingFiled
424B4 · ProspectusAug 14, 2025
EFFECT · Notice that a registration is effectiveAug 12, 2025
CERT · Exchange's certificate of listingAug 12, 2025
CORRESP · Letter to the SECAug 8, 2025
CORRESP · Letter to the SECAug 8, 2025
8-A12B · Registration of shares for listing on an exchangeAug 8, 2025
CORRESP · Letter to the SECAug 7, 2025
F-1/A · Registration statement, amendedAug 7, 2025
UPLOAD · Letter from the SECAug 6, 2025
FWP · Free writing prospectusJul 30, 2025
All 37 filings
FilingFiled
FWP · Free writing prospectusJul 28, 2025
CORRESP · Letter to the SECJul 28, 2025
F-1/A · Registration statement, amendedJul 28, 2025
UPLOAD · Letter from the SECJul 16, 2025
F-1 · Registration statementJul 9, 2025
DRSLTR · Letter to the SEC with a draftMay 21, 2025
DRS/A · Draft registration statement, amendedMay 21, 2025
UPLOAD · Letter from the SECMay 20, 2025
DRSLTR · Letter to the SEC with a draftMay 12, 2025
DRS/A · Draft registration statement, amendedMay 12, 2025
UPLOAD · Letter from the SECMay 7, 2025
DRSLTR · Letter to the SEC with a draftApr 29, 2025
DRS/A · Draft registration statement, amendedApr 29, 2025
UPLOAD · Letter from the SECApr 22, 2025
DRSLTR · Letter to the SEC with a draftApr 16, 2025
DRS/A · Draft registration statement, amendedApr 16, 2025
UPLOAD · Letter from the SECMar 28, 2025
DRSLTR · Letter to the SEC with a draftMar 21, 2025
DRS/A · Draft registration statement, amendedMar 21, 2025
UPLOAD · Letter from the SECFeb 18, 2025
DRS/A · Draft registration statement, amendedFeb 6, 2025
DRSLTR · Letter to the SEC with a draftFeb 5, 2025
UPLOAD · Letter from the SECJan 28, 2025
DRSLTR · Letter to the SEC with a draftDec 31, 2024
DRS/A · Draft registration statement, amendedDec 31, 2024
UPLOAD · Letter from the SECSep 27, 2024
DRS · Draft registration statementAug 30, 2024

Open IPO · From the cover of the final prospectus (424B4) filed Aug 14, 2025

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022
Revenue1.24B000
Research and development2.24M335.0K567.0K1.12M
Selling, general and administrative2.67M743.0K580.0K926.0K
Operating income-4.90M-1.08M-1.15M-2.04M
Interest expense-78.0K29.0K49.0K18.0K
Income before tax-5.80M-1.55M-1.00M-2.15M
Net income-5.86M-1.53M-1.05M-1.71M
Earnings per share, basic-0.72-0.22-0.15-0.19
Earnings per share, diluted-0.72-0.22-0.20

Balance sheet

LineFY2025FY2024FY2023FY2022
Cash and equivalents1.24M284.0K193.0K154.0K
Short-term investments3.05M0
Current assets4.86M457.0K444.0K417.0K
Property, plant and equipment14.0K
Total assets5.00M717.0K444.0K417.0K
Accounts payable829.0K651.0K655.0K771.0K
Current liabilities2.16M3.93M4.24M3.20M
Total debt118.0K1.80M2.46M1.57M
Total liabilities2.24M3.93M4.24M3.20M
Shareholders' equity2.77M-3.21M-3.80M-2.79M
Shares outstanding9.02M7.36M9.02M9.06M

Cash flow

LineFY2025FY2024FY2023FY2022
Cash from operations-4.92M-665.0K-1.03M-1.21M
Capital spending-14.0K000
Free cash flow-4.93M-665.0K-1.03M-1.21M
Cash from investing-3.01M-160.0K
Cash from financing8.92M770.0K1.05M1.24M
Change in cash980.0K101.0K39.0K-143.0K

Open Financials

Filings

FilingDateTypeFiled with
3 · Initial statement of ownershipNov 19, 2026Insider tradeSEC
4 · Change in ownershipNov 16, 2026Insider tradeSEC
6-K · Report of a foreign issuerNov 16, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
S-8 · Registration statement for employee plansOct 19, 2026Offer documentSEC
6-K · Report of a foreign issuerOct 8, 2026Current reportSEC
3 · Initial statement of ownershipSep 23, 2026Insider tradeSEC
4 · Change in ownershipSep 21, 2026Insider tradeSEC
424B5 · ProspectusSep 18, 2026Offer documentSEC
All 105 filings
FilingDateTypeFiled with
6-K · Report of a foreign issuerSep 18, 2026Current reportSEC
6-K · Report of a foreign issuerSep 14, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveSep 14, 2026Other filingsSEC
6-K · Report of a foreign issuerSep 4, 2026Current reportSEC
F-3 · Registration statementSep 1, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveAug 21, 2026Other filingsSEC
6-K · Report of a foreign issuerAug 19, 2026Current reportSEC
POS AM · Amendment to an effective registrationAug 18, 2026Offer documentSEC
6-K · Report of a foreign issuerAug 17, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
3 · Initial statement of ownershipJul 31, 2026Insider tradeSEC
4 · Change in ownershipJul 29, 2026Insider tradeSEC
6-K · Report of a foreign issuerJul 28, 2026Current reportSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
6-K · Report of a foreign issuerJun 9, 2026Current reportSEC
S-8 · Registration statement for employee plansMay 26, 2026Offer documentSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeApr 7, 2026Big-stake noticeSEC
4 · Change in ownershipApr 1, 2026Insider tradeSEC
EFFECT · Notice that a registration is effectiveApr 1, 2026Other filingsSEC
3 · Initial statement of ownershipMar 27, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 27, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 27, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 27, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 27, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 27, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 27, 2026Insider tradeSEC
3 · Initial statement of ownershipMar 27, 2026Insider tradeSEC
POS AM · Amendment to an effective registrationMar 27, 2026Offer documentSEC
6-K · Report of a foreign issuerMar 25, 2026Current reportSEC
20-F · Annual reportMar 25, 2026Annual reportSEC
6-K · Report of a foreign issuerMar 16, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveMar 16, 2026Other filingsSEC
CORRESP · Letter to the SECMar 11, 2026Other filingsSEC
6-K · Report of a foreign issuerMar 6, 2026Current reportSEC
UPLOAD · Letter from the SECMar 6, 2026Other filingsSEC
6-K · Report of a foreign issuerMar 4, 2026Current reportSEC
F-1 · Registration statementMar 2, 2026Offer documentSEC
DFeb 25, 2026Other filingsSEC
6-K · Report of a foreign issuerFeb 23, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 13, 2026Current reportSEC
6-K · Report of a foreign issuerFeb 11, 2026Current reportSEC
6-K · Report of a foreign issuerJan 29, 2026Current reportSEC
6-K · Report of a foreign issuerJan 20, 2026Current reportSEC
6-K · Report of a foreign issuerDec 29, 2025Current reportSEC
6-K · Report of a foreign issuerDec 22, 2025Current reportSEC
6-K · Report of a foreign issuerNov 20, 2025Current reportSEC
6-K · Report of a foreign issuerNov 18, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeNov 13, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 12, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 10, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerNov 3, 2025Current reportSEC
6-K · Report of a foreign issuerOct 8, 2025Current reportSEC
6-K · Report of a foreign issuerSep 30, 2025Current reportSEC
6-K · Report of a foreign issuerSep 5, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeAug 20, 2025Big-stake noticeSEC
6-K · Report of a foreign issuerAug 14, 2025Current reportSEC
424B4 · ProspectusAug 14, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveAug 13, 2025Other filingsSEC
CERT · Exchange's certificate of listingAug 12, 2025Other filingsSEC
CORRESP · Letter to the SECAug 8, 2025Other filingsSEC
CORRESP · Letter to the SECAug 8, 2025Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeAug 8, 2025Other filingsSEC
CORRESP · Letter to the SECAug 7, 2025Other filingsSEC
F-1/A · Registration statement, amendedAug 7, 2025Offer documentSEC
UPLOAD · Letter from the SECAug 6, 2025Other filingsSEC
FWP · Free writing prospectusJul 30, 2025Offer documentSEC
FWP · Free writing prospectusJul 28, 2025Offer documentSEC
CORRESP · Letter to the SECJul 28, 2025Other filingsSEC
F-1/A · Registration statement, amendedJul 28, 2025Offer documentSEC
UPLOAD · Letter from the SECJul 16, 2025Other filingsSEC
F-1 · Registration statementJul 9, 2025Offer documentSEC
DRSLTR · Letter to the SEC with a draftMay 21, 2025Other filingsSEC
DRS/A · Draft registration statement, amendedMay 21, 2025Offer documentSEC
UPLOAD · Letter from the SECMay 20, 2025Other filingsSEC
DRSLTR · Letter to the SEC with a draftMay 12, 2025Other filingsSEC
DRS/A · Draft registration statement, amendedMay 12, 2025Offer documentSEC
UPLOAD · Letter from the SECMay 7, 2025Other filingsSEC
DRSLTR · Letter to the SEC with a draftApr 29, 2025Other filingsSEC
DRS/A · Draft registration statement, amendedApr 29, 2025Offer documentSEC
UPLOAD · Letter from the SECApr 22, 2025Other filingsSEC
DRSLTR · Letter to the SEC with a draftApr 16, 2025Other filingsSEC
DRS/A · Draft registration statement, amendedApr 16, 2025Offer documentSEC
UPLOAD · Letter from the SECMar 28, 2025Other filingsSEC
DRSLTR · Letter to the SEC with a draftMar 21, 2025Other filingsSEC
DRS/A · Draft registration statement, amendedMar 21, 2025Offer documentSEC
UPLOAD · Letter from the SECFeb 18, 2025Other filingsSEC
DRSLTR · Letter to the SEC with a draftFeb 5, 2025Other filingsSEC
DRS/A · Draft registration statement, amendedFeb 5, 2025Offer documentSEC
UPLOAD · Letter from the SECJan 28, 2025Other filingsSEC
DRSLTR · Letter to the SEC with a draftDec 31, 2024Other filingsSEC
DRS/A · Draft registration statement, amendedDec 31, 2024Offer documentSEC
UPLOAD · Letter from the SECSep 27, 2024Other filingsSEC
DRS · Draft registration statementAug 30, 2024Offer documentSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Nasus Pharma Ltd.’s releases · as of Feb 13, 2026

Common shares
11,713,808
Fully diluted
14,409,226

Fully diluted

LineSharesAs of
Common shares11,713,808
Warrants2,695,418Feb 12, 2026

Warrants and options

Lot
Warrants · US$6.53 · expire about Feb 2028

Share count over time

CountShares
Nov 22, 202611,713,808

Open Cap table

Shareholders

TradeTradeSharesPriceValueDate
Teleman Dan Benjamin
Director, Officer: Chief Executive Officer
Buy6,550USD 3.10US$20,305Jun 17, 2026
Teleman Dan Benjamin
Director, Officer: Chief Executive Officer
Buy2,900USD 3.76US$10,904Apr 22, 2026
Teleman Dan Benjamin
Director, Officer: Chief Executive Officer
Buy15,000USD 2.04US$30,600Mar 31, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Brendan O’Grady
Other companies: Assertio Holdings, Inc. (CEO, Director · Since at least May 29, 2024); Teva Pharmaceutical Industries Limited (EVP, North America Commercial · Jan 1, 2018 – Mar 4, 2021 · Past)
Chief Executive Officer, Director · Since at least Jul 27, 2026
David Silberman
Other companies: Compugen Ltd. (Chief Financial Officer · Since at least Mar 18, 2026); Oramed Pharmaceuticals Inc. (Chief Financial Officer · Jul 5, 2021 – Jan 4, 2024 · Past)
Board Member · Since at least Mar 18, 2026
Eyal Rubin
Other companies: Protalix BioTherapeutics, Inc. (de) (Sr. VP and CFO · Sep 22, 2019 – Sep 23, 2024 · Past); Brainstorm Cell Therapeutics Inc. (CFO and Treasurer · Nov 20, 2017 – Nov 20, 2017 · Past)
Executive Vice President and Chief Financial Officer · Since at least Nov 20, 2025
Sharon Shacham
Other companies: Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); Karyopharm Therapeutics Inc. (Chief Scientific Officer · Sep 16, 2019 – Mar 29, 2022 · Past)
Board Member · Since at least Mar 18, 2026
Oren Elmaliah
Other companies: MySize, Inc. (CHIEF FINANCIAL OFFICER · Since at least May 1, 2017)
Interim CFO · Since at least Sep 19, 2026
Dalia MegiddoCo-founder, Board Member, Chief Development Officer · Since at least Nov 17, 2026
Isaac IsraelBoard Member · Since at least Nov 4, 2026
Nir SassiChief Financial Officer · Since Nov 11, 2026
Ronnie HershmanDirector · Since at least Mar 18, 2026
Ronnie HershmanBoard Member · Since at least Nov 4, 2026
All 11 people
PersonSeat
Udi GilboaExecutive Chairman · Since at least Aug 19, 2026

Open People

Log in to ask 6ix AI your own questions about Nasus Pharma Ltd.